3 New Strong Buy Ratings from Top-Rated Analysts: 03/04/2025

What stocks are enjoying the warm glow of positive analyst sentiment? We’ve unlocked a FREE sampling of our premium Strong Buy Stocks from Top Wall Street Analysts screener below: 

• Why analysts believe CarGurus Inc (NASDAQ: CARG) could see over 30% upside in the coming year. 
• Cheniere Energy Inc (NYSE: LNG) only has Buy and Strong Buy ratings among the analysts we track — no Hold, Sell, or Strong Sell ratings.
• BioMarin Pharmaceutical Inc (NASDAQ: BMRN) gets love from top-rated analysts following its recent earnings report. 

(P.S. You can get even more picks like this daily —  Try WallStreetZen Premium today)

1- CarGurus Inc (NASDAQ: CARG)

When it comes to used cars, whether you’re buying or selling, CarGurus is there to connect you with the best deals. With a history stretching back to 2006, one of the US’s most visited automotive marketplaces has quite a hefty checkbook at its disposal. To boot, the company’s recently had a fairly good earnings call — and the Street is quite confident that there’s a lot of upside to be had here.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $31.08 — get current quote > 

Max 1-year forecast:  $45.00

Why we’re watching:

• In total, 9 analysts track CARG stock — there’s an even division at play between 4 Strong Buy and 4 Buy ratings, with a lone Hold rating to round everything off. See the ratings
• Notably, the average 12-month price forecast for CarGurus shares implies a hefty 30.67% upside from current prices.
• Following the release of the company’s Q4 and FY 2024 report, JP Morgan’s Rajat Gupta (a top 10% rated analyst) maintained an earlier Strong Buy rating.
• The researcher hiked his price target to $42 from $40, calling the quarter’s results slightly better than expected to in line. 
• According to the analyst, CarGurus' continued success in the market was driven by its steady progress on both current and future product initiatives as "it gets deeper into dealer workflows."
• CARG carries an overall Zen Rating of A — in fact, it is in the top 2% of the stocks that we track.
• The stock’s Growth Component Grade rating is a particularly strong point — in this category, CarGurus stock is in the 97th percentile. With that being said, even that impressive achievement pales in comparison to the marketplace’s strength when it comes to Financials rating — in which it ranks in the top 1%. (See all 7 Zen Component Grades here >)

2- Cheniere Energy Inc (NYSE: LNG)

When it comes to liquid natural gas (LNG), Cheniere Energy, which trades under the very appropriate ticker LNG, is an industry titan. This is the largest U.S.-based exporter of LNG — as well as the second-largest producer in the entire world. A recently released earnings call delivered a double beat — and despite rising operational costs impacting the bottom line, the stock still maintains high ratings in key metrics.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $216.04 — get current quote > 

Max 1-year forecast: $265.00

Why we’re watching:

• There’s a rarely-seen level of unambiguous support for Cheniere Energy stock — of the 10 Wall Street researchers who cover it, 8 deem it a Strong Buy, while 2 rate it a Buy. See the ratings
• The most recent revision came from Benjamin Nolan of Stifel Nicolaus (a top 15% rated analyst), who reiterated a prior Strong Buy rating and increased his price target from $237 to $255.
• While Cheniere’s earnings per share (EPS) and revenue in Q4 beat consensus estimates, the business did not beat Stifel Nicolaus’ EPS estimates. However, the analyst said that "growth continues moving forward with the company looking to hit the regulatory approval window created by the Trump administration and the company making final investment decisions on Corpus Christi Train 8 and 9 in 2025 and Sabine Pass Stage 5 in 2026."
• With that said, although the firm’s lofty expectations were not met, Q4 marked the third consecutive quarter in which Cheniere beat consensus estimates for EPS.
• LNG stock carries a Zen Rating of B — equities with that distinction have provided an average annual return of 19.88% since the early 2000s.
• While it scores well in terms of Momentum, Financials, and Artificial Intelligence, Cheniere Energy’s Sentiment Component Grade rating is the star of the show — as it is ranked in the top 3% of stocks in that category. (See all 7 Zen Component Grades here >)

3- BioMarin Pharmaceutical Inc (NASDAQ: BMRN)

A lot of us tend to reflexively run for the hills at the mention of biotech stocks — but BioMarin has been in business for 27 years. More to the point, in that time, the company has risen to a $13.5 billion market cap — this isn’t some ambitious yet risky startup. With a robust pipeline of treatments aimed at rare diseases and a standout performance in 2024’s last quarter, BioMarin is increasingly looking like one of the best biotech bets in the market.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $71.17  — get current quote > 

Max 1-year forecast:  $126.00

Why we’re watching:

• At present, 19 equity researchers issue ratings for BMRN. The Buy and Hold ratings stand evenly matched, with 5 analysts apiece — but the 9 Strong Buy ratings steal the show. See the ratings
• Eliana Merle of UBS (a top 26% rated analyst) reissued a Strong Buy rating on BioMarin stock on February 20. In addition, she increased her 12-month price forecast from $109 to $113.
• Merle’s revision came after the company’s Q4 report, which saw sales, earnings, and revenues come in above estimates.
• Looking ahead, the analyst said that Voxzogo still has plenty of room to grow in terms of greater penetration of the achondroplasia market and long-term expansion.
• Merle detailed that UBS believes the opportunity for Voxzogo in indications beyond achondroplasia remains significantly underappreciated and could be $5B+.
• With an overall Zen Rating of A, BMRN stock is in good company — stocks that earn this distinction have provided an average annual return of 32.52%.
• Value, in which the stock ranks in the top 4% of the more than 4,600 equities that we track, is BioMarin’s strong suit — but we wouldn’t discount its Financial rating either, as it is in the 92nd percentile in that category. (See all 7 Zen Component Grades here >)

What to Do Next?

• 8 Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return > 
• 4 Step Process to Find More 100%+ Stock Winners >

Want to get in touch? Email us at news@wallstreetzen.com.